{"sourcedb":"DevicePMAs@therightstef","sourceid":"P000054_S040","text":"Approval for extension of the rhbmp-2 drug substance expiration date from 60 to 72 months using the approved expiration date modification protocol. the device, as modified, will be marketed under the trade name infusebone graft and is indicated for the following: treating acute, open tibial shaft fractures that have been stabilized with im nail fixation after appropriate wound management. infuse bone graft must be applied within 14 days after the initial fracture. prospective patients should be skeletally mature.","project":"consensus_PMA_Age_Indications"}